TNFRSF4 and gastric cancer: An open-label, nonrandomized, controlled phase I trial, NCT04198766, is currently in the recruitment phase to study the safety and tolerable dosage of the OX40 agonist INBRX-106-Hexavalent, alone or in combination with pembrolizumab, in 200 patients with advanced solid tumors, including gastric cancer, as second/third-line therapy.